Oruka Therapeutics: senior VP finance Agarwal Arjun sold 9,999 shares

What happened

• Agarwal Arjun, senior vice president, finance, exercised options for a total of 9,999 shares and sold 9,999 shares on Oct 12, 2026. The exercises were 8,541 shares at $12.50 for $106,763 and 1,458 shares at $34.39 for $50,141. The open-market sales were 5,741 shares at a weighted average $80.03 for $459,453; 2,100 shares at a weighted average $80.76 for $169,596; 1,958 shares at a weighted average $81.86 for $160,272; and 200 shares at a weighted average $82.83 for $16,567. The filing also lists two derivative dispositions at $0.00 for 8,541 and 1,458 shares.

Key details

• Transaction date(s) and price(s): Oct 12, 2026 — exercised 8,541 @ $12.50 ($106,763) and 1,458 @ $34.39 ($50,141); sold 5,741 @ $80.03 ($459,453), 2,100 @ $80.76 ($169,596), 1,958 @ $81.86 ($160,272), 200 @ $82.83 ($16,567).
• Shares owned after the transaction: not reported in the filing.
• Footnotes that matter: sales were effected pursuant to a Rule 10b5-1 trading plan entered Feb 11, 2026 (F1); sale prices are weighted averages with reported ranges for each block (F2–F5); vesting schedules for the options are noted (vesting monthly from Jan 1, 2025 and Jan 1, 2026) (F6, F7).
• Filing timeliness: Form 4 filed Oct 13, 2026 for Oct 12, 2026 transactions (no late filing indicated).

Why it may matter

• The filing shows exercised options and the same number of shares were sold on the same day, consistent with a cashless exercise or immediate sale of exercised shares.
• The open-market sales were executed under a Rule 10b5-1 plan.
• The filing does not show why the insider traded or why the company acted.